[go: up one dir, main page]

CY1122328T1 - Ανοσο-βασιζομενες δοκιμασιες δραστικοτητας οροτυπου a βοτουλινικης τοξινης - Google Patents

Ανοσο-βασιζομενες δοκιμασιες δραστικοτητας οροτυπου a βοτουλινικης τοξινης

Info

Publication number
CY1122328T1
CY1122328T1 CY20191101100T CY191101100T CY1122328T1 CY 1122328 T1 CY1122328 T1 CY 1122328T1 CY 20191101100 T CY20191101100 T CY 20191101100T CY 191101100 T CY191101100 T CY 191101100T CY 1122328 T1 CY1122328 T1 CY 1122328T1
Authority
CY
Cyprus
Prior art keywords
serovyp
immune
botulinum toxin
based assays
toxin activity
Prior art date
Application number
CY20191101100T
Other languages
English (en)
Inventor
Ester Fernandez-Salas
Joanne Wang
Patton E. Garay
Lina S. Wong
D. Diane Hodges
Kei Roger Aoki
Original Assignee
Allergan, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40677745&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1122328(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan, Inc. filed Critical Allergan, Inc.
Publication of CY1122328T1 publication Critical patent/CY1122328T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/085—Picornaviridae, e.g. coxsackie virus, echovirus, enterovirus
    • C07K14/10—Hepatitis A virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/33—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/952—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)

Abstract

Η παρούσα εφεύρεση εστιάζεται σε μία μέθοδο ανίχνευσης αντι-ΒοΝΤ/Α εξουδετερωτικών αντισωμάτων.
CY20191101100T 2008-03-14 2019-10-23 Ανοσο-βασιζομενες δοκιμασιες δραστικοτητας οροτυπου a βοτουλινικης τοξινης CY1122328T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US3672308P 2008-03-14 2008-03-14
EP20120187775 EP2578601A1 (en) 2008-03-14 2009-03-13 Immuno-based botulinum toxin serotype A activity assays
PCT/US2009/037046 WO2009114748A1 (en) 2008-03-14 2009-03-13 Immuno-based botulinum toxin serotype a activity assays
EP09719709.9A EP2271670B1 (en) 2008-03-14 2009-03-13 Immuno-based botulinum toxin serotype a activity assays

Publications (1)

Publication Number Publication Date
CY1122328T1 true CY1122328T1 (el) 2021-01-27

Family

ID=40677745

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20141100972T CY1115771T1 (el) 2008-03-14 2014-11-21 Ανοσο-βασιζομενες δοκιμασιες δραστικοτητας οροτυπου α βοτουλινικης τοξινης
CY20191101100T CY1122328T1 (el) 2008-03-14 2019-10-23 Ανοσο-βασιζομενες δοκιμασιες δραστικοτητας οροτυπου a βοτουλινικης τοξινης

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20141100972T CY1115771T1 (el) 2008-03-14 2014-11-21 Ανοσο-βασιζομενες δοκιμασιες δραστικοτητας οροτυπου α βοτουλινικης τοξινης

Country Status (26)

Country Link
US (11) US8198034B2 (el)
EP (6) EP4588519A3 (el)
JP (5) JP5766954B2 (el)
KR (1) KR101609894B1 (el)
CN (2) CN102356091A (el)
AU (1) AU2009223161B2 (el)
BR (2) BR122012027456A2 (el)
CA (1) CA2715033C (el)
CO (1) CO6311001A2 (el)
CY (2) CY1115771T1 (el)
DK (2) DK2271670T3 (el)
ES (2) ES2755505T3 (el)
HR (1) HRP20191886T1 (el)
HU (1) HUE046037T2 (el)
IL (2) IL208097A (el)
LT (1) LT3031825T (el)
MX (1) MX2010010137A (el)
MY (2) MY165032A (el)
NZ (1) NZ588029A (el)
PL (2) PL3031825T3 (el)
PT (2) PT2271670E (el)
RU (2) RU2491293C2 (el)
SG (1) SG2014009112A (el)
SI (2) SI2271670T1 (el)
UA (1) UA102247C2 (el)
WO (1) WO2009114748A1 (el)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7563874B2 (en) 1998-08-31 2009-07-21 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US8497081B2 (en) 2004-02-24 2013-07-30 Allergan, Inc. Botulinum toxin screening assays
US8598321B2 (en) 2007-03-22 2013-12-03 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
JP5432727B2 (ja) * 2008-01-29 2014-03-05 株式会社抗体研究所 Ａ型ボツリヌス毒素中和組成物及びヒト抗ａ型ボツリヌス毒素抗体
KR101604515B1 (ko) * 2008-03-14 2016-03-17 알러간, 인코포레이티드 면역-기반 보툴리눔 독소 세로타입 ａ 활성 검정
EP4588519A3 (en) 2008-03-14 2025-10-15 Allergan, Inc. Immuno-based botulinum toxin serotype a activity assays
WO2010014854A2 (en) 2008-07-31 2010-02-04 The Regents Of The University Of California Antibodies that neutralize botulinum neurotoxins
RU2543650C2 (ru) * 2009-03-13 2015-03-10 Аллерган, Инк. Иммунологические тесты на активность эндопептидаз с измененной нацеленностью
ES2689703T3 (es) 2009-03-13 2018-11-15 Allergan, Inc. Células útiles para ensayos de actividad de serotipo A de toxina botulínica basados en la respuesta inmunológica
AU2015203359A1 (en) * 2009-03-13 2015-07-02 Allergan, Inc. Cells useful for immuno-based Botulinum toxin serotype A activity assays
US8129139B2 (en) 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin
WO2011022438A2 (en) * 2009-08-18 2011-02-24 Us Army Medical Research And Materiel Command Cleavage sensitive antibodies and methods of use thereof
JP2013511264A (ja) * 2009-11-18 2013-04-04 メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト アウフ アクティーン クロストリジウム神経毒を定量化するためのアッセイ
US9243057B2 (en) 2010-08-31 2016-01-26 The Regents Of The University Of California Antibodies for botulinum neurotoxins
US10908146B2 (en) 2011-06-01 2021-02-02 Biomadison, Inc. Compositions and methods for improving sensitivity in cell based assays
US9303285B2 (en) 2012-01-04 2016-04-05 Biomadison, Inc. Methods and compounds for increasing sensitivity of botulinum assays
BR112013030964B1 (pt) 2011-06-01 2022-08-16 Biomadison, Inc Ensaio botulínico de não fret
HUE037509T2 (hu) 2011-09-29 2018-09-28 Cellsnap Llc Készítmények és eljárások toxigenicitás meghatározására
KR20140107195A (ko) 2011-11-25 2014-09-04 프라운호퍼-게젤샤프트 추르 푀르데룽 데어 안제반텐 포르슝 에 파우 Ｓｎａｐ／ｃｌｉｐ 태그의 검출용 단일클론 항체
WO2013102088A2 (en) 2011-12-31 2013-07-04 Allergan, Inc. Highly Sensitive Cell-Based Assay to Detect the Presence of Active Botulinum Neurotoxin Serotype-A
WO2013103737A1 (en) 2012-01-04 2013-07-11 Biomadison, Inc. Methods and compounds for increasing sensitivity of botulinum assays
US10125350B2 (en) 2012-10-16 2018-11-13 Merz Pharma Gmbh & Co. Kgaa Cellular test systems for the determination of the biological activities of neurotoxin polypeptides
CA2880897C (en) 2012-11-21 2020-01-14 Syntaxin Limited Methods for the manufacture of proteolytically processed polypeptides
WO2014100019A1 (en) 2012-12-18 2014-06-26 Allergan, Inc. Prophylactic treatment of herpes recurrence
CN105339790B (zh) * 2013-06-28 2018-04-17 莫茨制药有限及两合公司 用于确定神经毒素多肽在细胞中的生物活性的工具和方法
LT3270162T (lt) 2013-08-09 2020-09-10 Biomadison, Inc. Padidinto jautrumo botulino toksino tyrimas
US10408837B2 (en) * 2013-12-09 2019-09-10 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Peptide substrates recognizable by type E botulinum neurotoxin
EP3760186A1 (en) 2014-04-30 2021-01-06 Allergan, Inc. Formulations of biologics for intravesical instillation
ES2642916T3 (es) 2014-06-06 2017-11-20 Galit KLEINER-FISMAN Toxina botulínica para su uso en el tratamiento de la paratonia
EP3567055A1 (en) 2014-07-07 2019-11-13 Allergan, Inc. Method of detecting cleaved snap25 in tissue samples
AU2015287964A1 (en) 2014-07-07 2017-02-16 Allergan, Inc. Method of detecting cleaved SNAP25 in tissue samples
ES2821731T3 (es) 2014-07-31 2021-04-27 Allergan Inc Formulaciones de productos biológicos para instilación intravesical
CA2968284C (en) 2014-11-21 2023-11-14 Merz Pharma Gmbh & Co. Kgaa Methods for the determination of the biological activities of neurotoxin polypeptides
JP6772138B2 (ja) * 2014-12-19 2020-10-21 メルツ ファルマ ゲーエムベーハー ウント コンパニー カーゲーアーアー 細胞内のＢｏＮＴ／Ｅの生物学的活性を決定するための手段及び方法
EP3590500B1 (en) 2014-12-23 2025-06-25 Merz Pharma GmbH & Co. KGaA Botulinum toxin prefilled container
US9527922B2 (en) 2014-12-31 2016-12-27 Development Center For Biotechnology Humanized alpha-enolase specific antibodies and methods of uses in cancer therapy
CN107427563B (zh) * 2014-12-31 2021-03-02 财团法人生物技术开发中心 人源化α-烯醇酶特异性抗体及用于癌症治疗的方法
TWI704156B (zh) * 2015-03-04 2020-09-11 德商曼茲法瑪股份有限公司 用於增進肉毒桿菌神經毒素進入細胞之特定攝取的方法
JP6412471B2 (ja) 2015-07-15 2018-10-24 富士フイルム株式会社 含窒素複素環化合物の製造方法およびその中間体
WO2017049251A2 (en) * 2015-09-18 2017-03-23 Tioma Therapeutics, Inc. Therapeutic cd47 antibodies
WO2017063743A1 (en) 2015-10-14 2017-04-20 Merz Pharma Gmbh & Co. Kgaa Improvements to ultrasound-based therapy of photoaged tissue
AU2017227978B2 (en) 2016-03-02 2022-03-10 Merz Pharma Gmbh & Co. Kgaa Composition comprising botulinum toxin
TWI737742B (zh) 2016-06-22 2021-09-01 德商梅茲製藥有限兩合公司 肉毒桿菌毒素的預填充式注射器系統、具有其之套組以及其之使用
EP3290437A1 (en) 2016-08-31 2018-03-07 Merz Pharma GmbH & Co. KGaA Novel recombinant clostridial neurotoxins with decreased duration of effect
RU2762607C2 (ru) 2016-09-13 2021-12-21 Аллерган, Инк. Стабилизированные небелковые композиции клостридиального токсина
EP3312193A1 (en) 2016-10-19 2018-04-25 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum neurotoxins with accelerated onset of effect
EP3529276A4 (en) 2016-10-21 2020-06-17 Arch Oncology, Inc. CD47 THERAPEUTIC ANTIBODIES
EP3333179A1 (en) 2016-12-07 2018-06-13 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum toxin with accelarated onset of effect
EP3335719A1 (en) 2016-12-14 2018-06-20 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum neurotoxins with a stabilized light chain
IL268688B2 (en) 2017-03-24 2024-01-01 Merz Pharma Gmbh & Co Kgaa Improved use of botulinum toxin to treat sialorrhea
US11952601B2 (en) 2017-06-20 2024-04-09 Merz Pharma Gmbh & Co. Kgaa Recombinant botulinum toxin with increased duration of effect
EP3649143B1 (en) 2017-07-06 2022-08-31 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum neurotoxins with increased duration of effect
US20210008156A1 (en) 2017-10-26 2021-01-14 Merz Pharma Gmbh & Co. Kgaa Novel recombinant botulinum neurotoxins with increased duration of effect
US20200354706A1 (en) 2017-11-22 2020-11-12 Merz Pharma Gmbh & Co. Kgaa Novel recombinant botulinum toxin with increased duration of effect
US11707510B2 (en) * 2018-02-16 2023-07-25 Preclinics Discovery Gmbh Nucleic acid-based botulinum neurotoxin for therapeutic use
JP6544669B1 (ja) 2018-03-16 2019-07-17 ディヴェロップメント センター フォー バイオテクノロジー アルファエノラーゼに特異的な抗体及びその使用
EP3860640A1 (en) 2018-10-02 2021-08-11 Merz Pharma GmbH & Co. KGaA Novel uses of botulinum neurotoxin for treating lipoedema
EP3660509B1 (en) 2018-11-29 2022-03-09 Hugel Inc. A cell-based method for determining an activity of botulinum toxin
KR101983216B1 (ko) * 2018-11-29 2019-05-29 주식회사 에이비바이오 보툴리눔 독소 활성을 결정하기 위한 항체, 및 이를 이용한 활성 측정방법
KR102251096B1 (ko) * 2018-12-12 2021-05-13 휴젤(주) 보툴리눔 독소 활성을 결정하는 세포 기반 방법
IL285634B2 (en) 2019-02-21 2025-06-01 Merz Pharma Gmbh Co Kgaa Novel uses of botulinum neurotoxin for the treatment of tremor
KR102274841B1 (ko) * 2019-10-16 2021-07-12 주식회사 하울바이오 Snare 복합체를 억제하는 항-snap 25 항체 및 이의 용도
US20230329996A1 (en) 2020-06-05 2023-10-19 Merz Pharma Gmbh & Co. Kgaa High dose and low volume botulinum toxin treatment of facial wrinkles
US20220010355A1 (en) * 2020-07-10 2022-01-13 Galderma Holding SA Cell based method for determination of botulinum toxin potency based on western blotting
KR102797145B1 (ko) * 2021-05-24 2025-04-22 주식회사 에이티지씨 렌티바이러스에 의해 특정 유전자가 삽입된 보툴리눔 독소에 민감한 세포
WO2022250405A1 (ko) * 2021-05-24 2022-12-01 주식회사 에이티지씨 렌티바이러스에 의해 특정 유전자가 삽입된 보툴리눔 독소에 민감한 세포
TW202400223A (zh) 2022-02-15 2024-01-01 德商梅茲製藥有限兩合公司 液體製劑及其製備方法與用途
IL315004A (en) 2022-02-15 2024-10-01 Merz Pharma Gmbh & Co Kgaa : Liquid botulinum toxin formulation and its uses
TW202400122A (zh) 2022-02-28 2024-01-01 德商梅茲製藥有限兩合公司 肉毒桿菌毒素用於降低皮膚毛孔尺寸及／或皮脂產生之用途、以及降低皮膚毛孔尺寸及／或皮脂產生的方法
EP4526678A1 (en) * 2022-04-21 2025-03-26 Biomadison, Inc. Cell based assays for botulinum neurotoxin
WO2024102345A1 (en) 2022-11-07 2024-05-16 Allergan, Inc. Prevention of post-operative atrial fibrillation with a botulinum toxin
AU2023400491A1 (en) 2022-11-28 2025-04-10 Merz Pharma Gmbh & Co. Kgaa Botulinum toxin injection in platysma for lower face and neck rejuvenation
CN120379640A (zh) 2022-11-28 2025-07-25 莫茨药物股份两合公司 用于颈部年轻化的高浓度肉毒杆菌毒素治疗
CN120225172A (zh) 2022-12-15 2025-06-27 莫茨药物股份两合公司 包含肉毒杆菌毒素的可注射凝胶及其用途
CH720444A2 (de) 2023-01-20 2024-07-31 Abbvie Inc Clostridium botulinum serotyp a neurotoxin (bont/a)- sequenzvarianten
CH720447A2 (de) 2023-01-20 2024-07-31 Abbvie Inc Zusammensetzungen von clostridium botulinum neurotoxin serotyp a
CN120882478A (zh) 2023-03-15 2025-10-31 莫茨药物股份两合公司 用于处理至少一个流体样品的摇摆式振荡器
WO2024194181A1 (en) 2023-03-20 2024-09-26 Merz Therapeutics GmbH Nh3 scavenger for use in the treatment of mobility disability in a post-stroke patient
AU2024274999A1 (en) 2023-05-23 2025-11-13 Merz Therapeutics GmbH Botulinum toxin for treating peripheral neuropathic pain
AU2024288687A1 (en) 2023-07-12 2025-10-23 Merz Pharma Gmbh & Co. Kgaa Treatment of hyperpigmentation conditions by botulinum toxin
AR133528A1 (es) 2023-08-10 2025-10-08 Merz Pharma Gmbh & Co Kgaa Formulación líquida de toxina botulínica y su uso
DE102025101336A1 (de) 2024-01-19 2025-07-24 Abbvie Inc. Zusammensetzungen von clostridium botulinum neurotoxin serotyp a und verbesserte trocknungsprozesse
WO2025228877A1 (en) 2024-04-29 2025-11-06 Merz Therapeutics GmbH Botulinum toxin for the preventive treatment of migraine

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3672308A (en) 1970-11-06 1972-06-27 Westinghouse Electric Corp Roadway switching arrangement for transportation system having center guiderail below track level
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5955584A (en) * 1986-03-31 1999-09-21 Charter Ventures Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US5670617A (en) 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
AU7492291A (en) 1990-02-26 1991-09-18 Board Of Trustees Of The Leland Stanford Junior University Identification and expression of insect steroid receptor dna sequences
GB9206318D0 (en) 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5962255A (en) 1992-03-24 1999-10-05 Cambridge Antibody Technology Limited Methods for producing recombinant vectors
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
AU685054C (en) 1992-05-14 2003-02-27 Baylor College Of Medicine Mutated steroid hormone receptors, methods for their use and molecular switch for gene therapy
US5364791A (en) 1992-05-14 1994-11-15 Elisabetta Vegeto Progesterone receptor having C. terminal hormone binding domain truncations
JP3510886B2 (ja) 1992-06-23 2004-03-29 ボツリヌム トキシン リサーチ アソシエイト インコーポレイテッド ボツリヌスｂ複合体を含有する医薬組成物
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
SE9304060D0 (sv) 1993-12-06 1993-12-06 Bioinvent Int Ab Sätt att selektera specifika bakteriofager
GB9411138D0 (en) * 1994-06-03 1994-07-27 Microbiological Res Authority Toxin assay
US5962637A (en) 1994-06-03 1999-10-05 Microbiological Research Authority Toxin assay
US6495518B1 (en) 1994-06-13 2002-12-17 Vanderbilt University Method for importing biologically active molecules into cells
US5807746A (en) 1994-06-13 1998-09-15 Vanderbilt University Method for importing biologically active molecules into cells
GB9500851D0 (en) 1995-01-17 1995-03-08 Bionvent International Ab Method of selecting specific bacteriophages
EP0833911B1 (en) * 1995-06-07 2004-05-12 Ortho Pharmaceutical Corporation Cdr-grafted anti-tissue factor antibodies and methods of use thereof
FR2739621B1 (fr) 1995-10-05 1997-12-05 Centre Nat Rech Scient Peptides utilisables comme vecteurs pour l'adressage intracellulaire de molecules actives
US6072041A (en) 1996-06-03 2000-06-06 Case Western Reserve University Fusion proteins for protein delivery
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
CA2291074C (en) 1997-05-21 2008-04-01 The Board Of Trustees Of The Leland Stanford Junior University Composition and method for enhancing transport across biological membranes
US6248558B1 (en) 1998-03-31 2001-06-19 Vanderbilt University Sequence and method for genetic engineering of proteins with cell membrane translocating activity
ATE512225T1 (de) * 1998-04-03 2011-06-15 Chugai Pharmaceutical Co Ltd Humanisierter antikörper gegen den menschlichen gewebefaktor (tf) und verfahren für die konstruktion eines solchen humanisierten antikörpers.
US7563874B2 (en) 1998-08-31 2009-07-21 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
JP2002531113A (ja) 1998-12-10 2002-09-24 ワシントン大学 蛋白質の形質導入システムおよびその使用法
US7034132B2 (en) 2001-06-04 2006-04-25 Anderson David W Therapeutic polypeptides, nucleic acids encoding same, and methods of use
DE19925739A1 (de) * 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
AU777556B2 (en) 1999-08-25 2004-10-21 Allergan, Inc. Activatable recombinant neurotoxins
US20030008813A1 (en) 1999-12-17 2003-01-09 Felgner Philip L. Intracellular protein delivery compositions and methods of use
GB9930519D0 (en) 1999-12-24 2000-02-16 Phogen Limited Uses of transport proteins
AU2001233027A1 (en) 2000-01-27 2001-08-07 Genetics Institute, Llc Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
US6294553B1 (en) 2000-02-15 2001-09-25 Allergan Sales, Inc. Method for treating ocular pain
US6325899B1 (en) 2000-03-10 2001-12-04 Action Caps, Llc Disposable and recyclable intermediates for use in electrostatic coating processes
US20040220100A1 (en) 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
US20030219462A1 (en) 2000-07-21 2003-11-27 Allergan Sales, Inc Clostridial neurotoxin compositions and modified clostridial neurotoxins
US7491799B2 (en) 2000-07-21 2009-02-17 Allergan, Inc. Modified botulinum neurotoxins
AU8466501A (en) 2000-07-21 2002-02-05 Essentia Biosystems Inc Multi-component biological transport systems
EP1305333A4 (en) 2000-07-31 2006-04-12 Active Motif PEPTIDE-MEDIATED DELIVERY OF MOLECULES IN CELLS
US6678651B2 (en) * 2000-09-15 2004-01-13 Mindspeed Technologies, Inc. Short-term enhancement in CELP speech coding
WO2002036758A2 (en) * 2000-11-06 2002-05-10 United States Army Medical Research And Material Command Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
US7223577B2 (en) 2000-11-17 2007-05-29 Allergan, Inc. Post-translational modifications and Clostridial neurotoxins
US8022172B2 (en) 2001-08-28 2011-09-20 Allergan, Inc. Luminescence resonance energy transfer (LRET) assays for clostridial toxin activity
US7332567B2 (en) 2001-08-28 2008-02-19 Allergan, Inc. Fret protease assays for clostridial toxins
US7374896B2 (en) 2001-08-28 2008-05-20 Allergan, Inc. GFP-SNAP25 fluorescence release assay for botulinum neurotoxin protease activity
US7208285B2 (en) 2001-08-28 2007-04-24 Allergan, Inc. Fret protease assays for botulinum serotype A/E toxins
US20080064054A1 (en) * 2001-08-28 2008-03-13 Ester Fernandez-Salas Fluorescence resonance energy transfer (fret) assays for clostridial toxin activity
AU2002360377A1 (en) * 2001-11-09 2003-05-19 The Ohio State University Research Foundation Baalc expression as a diagnostic marker for acute leukemia
AU2003216389A1 (en) 2002-02-21 2003-09-09 Essentia Biosystems, Inc. Induction of hair growth with vascular endothelial growth factor
KR100708398B1 (ko) 2002-03-22 2007-04-18 (주) 에이프로젠 인간화 항체 및 이의 제조방법
US20040057958A1 (en) 2002-05-17 2004-03-25 Waggoner David W. Immunogenicity-enhancing carriers and compositions thereof and methods of using the same
RU2230325C2 (ru) * 2002-08-15 2004-06-10 Научно-исследовательский институт микробиологии Министерства обороны Российской Федерации Способ приготовления очищенного препарата ботулинического токсина типа а
US7183066B2 (en) 2002-09-27 2007-02-27 Allergan, Inc. Cell-based fluorescence resonance energy transfer (FRET) assays for clostridial toxins
US7166692B2 (en) 2003-03-04 2007-01-23 Canbrex Bio Science Walkersville, Inc. Intracellular delivery of small molecules, proteins, and nucleic acids
US7341843B2 (en) * 2003-04-11 2008-03-11 Allergan, Inc. Botulinum toxin A peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy
EP2332959B1 (en) * 2003-12-19 2014-11-26 Wisconsin Alumni Research Foundation Method and compositions for detecting botulinum neurotoxin
JP4970057B2 (ja) * 2004-02-24 2012-07-04 アラーガン、インコーポレイテッド ボツリヌス毒素スクリーニングアッセイ
US8497081B2 (en) * 2004-02-24 2013-07-30 Allergan, Inc. Botulinum toxin screening assays
ES2691498T3 (es) 2004-03-03 2018-11-27 Revance Therapeutics, Inc. Aplicación tópica y liberación transdérmica de toxinas botulínicas
AU2011253597B2 (en) 2004-03-03 2014-12-04 Revance Therapeutics, Inc. Multi-component biological transport systems
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
JP2007527431A (ja) 2004-03-03 2007-09-27 ルバンス セラピュティックス 局所的診断及び治療用の輸送のための組成物及び方法
JP4932480B2 (ja) 2004-06-03 2012-05-16 千寿製薬株式会社 アミド化合物を含有する角膜知覚回復剤
US7906276B2 (en) * 2004-06-30 2011-03-15 Kimberly-Clark Worldwide, Inc. Enzymatic detection techniques
US7514088B2 (en) 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
US7399607B2 (en) 2004-09-22 2008-07-15 Allergan, Inc. Fluorescence polarization assays for determining clostridial toxin activity
US20070258992A1 (en) * 2004-10-06 2007-11-08 Atassi M Zouhair Determining and Reducing Immunoresistance to Botulinum Toxin Therapy Using Botulinum Toxin a Peptides
GB0426394D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
EP1861112A4 (en) 2005-03-03 2009-07-22 Revance Therapeutics Inc COMPOSITIONS AND METHODS FOR TOPICAL APPLICATION AND TRANSDERMAL DELIVERY OF BOTULINUM TOXINES
JP2008535486A (ja) 2005-03-15 2008-09-04 アラーガン、インコーポレイテッド クロストリジウム毒素標的細胞に対する改変された標的能力を有する修飾クロストリジウム毒素
US8124357B2 (en) * 2005-04-05 2012-02-28 Allergan, Inc. Lipophilic dye-based fret assays for clostridal toxin activity
ES2351942T3 (es) * 2005-04-05 2011-02-14 Allergan Inc Analisis de la actividad de una toxina clostridial.
WO2007047342A1 (en) 2005-10-12 2007-04-26 Allergan, Inc. Assays of molecular or subcellular interactivity using depolarization after resonance energy transfer (daret)
CA2629499A1 (en) 2005-11-17 2007-05-24 Revance Therapeutics, Inc. Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
GB2437311A (en) * 2006-04-07 2007-10-24 Mologic Ltd A protease detection product
US8796429B2 (en) 2006-05-31 2014-08-05 Lpath, Inc. Bioactive lipid derivatives, and methods of making and using same
PL2027156T3 (pl) * 2006-06-02 2011-06-30 Aveo Pharmaceuticals Inc Białka wiążące czynnik wzrostowy hapatocytów (HGF)
CA2658260A1 (en) 2006-07-11 2008-01-17 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
MY142256A (en) 2006-09-14 2010-11-15 Revance Therapeutics Inc Compositions and methods for topical diagnostic and therapeutic transport
CN100577149C (zh) * 2006-12-21 2010-01-06 北京民海生物科技有限公司 一种治疗用a型肉毒毒素冻干粉针剂新型冻干保护剂配方
AU2007340158A1 (en) 2006-12-29 2008-07-10 Revance Therapeutics, Inc. Transport molecules using reverse sequence HIV-TAT polypeptides
AU2007340162B2 (en) 2006-12-29 2013-08-01 Revance Therapeutics, Inc. Compositions and methods of topical application and transdermal delivery of botulinum toxins stabilized with polypeptide fragments derived from HIV-TAT
US8753831B2 (en) * 2007-06-05 2014-06-17 City Of Hope Methods for detection of botulinum neurotoxin
BRPI0813627B1 (pt) 2007-07-26 2021-09-14 Revance Therapeutics, Inc Composição farmacêutica ou cosmética compreendendo um peptídeo catiônico e kit para administração da mesma
WO2009039356A1 (en) 2007-09-20 2009-03-26 Allergan, Inc. Treatment methods with brimonidine
EP4588519A3 (en) 2008-03-14 2025-10-15 Allergan, Inc. Immuno-based botulinum toxin serotype a activity assays
KR101604515B1 (ko) 2008-03-14 2016-03-17 알러간, 인코포레이티드 면역-기반 보툴리눔 독소 세로타입 ａ 활성 검정
LT2379104T (lt) 2008-12-31 2018-04-10 Revance Therapeutics, Inc. Injekcinės botulino toksino vaisto formos
ES2689703T3 (es) * 2009-03-13 2018-11-15 Allergan, Inc. Células útiles para ensayos de actividad de serotipo A de toxina botulínica basados en la respuesta inmunológica
RU2543650C2 (ru) 2009-03-13 2015-03-10 Аллерган, Инк. Иммунологические тесты на активность эндопептидаз с измененной нацеленностью
LT5982B (lt) * 2012-04-24 2013-12-27 Uab Friday Lab Su planšetiniu kompiuteriu arba išmaniuoju telefonu suderintas žuvų ieškiklis
US10125350B2 (en) * 2012-10-16 2018-11-13 Merz Pharma Gmbh & Co. Kgaa Cellular test systems for the determination of the biological activities of neurotoxin polypeptides
AU2013349725B2 (en) * 2012-11-21 2016-05-12 Merz Pharma Gmbh & Co. Kgaa Means and methods for determination of botulinum neurotoxin biological activity
EP3567055A1 (en) * 2014-07-07 2019-11-13 Allergan, Inc. Method of detecting cleaved snap25 in tissue samples
JP6772138B2 (ja) * 2014-12-19 2020-10-21 メルツ ファルマ ゲーエムベーハー ウント コンパニー カーゲーアーアー 細胞内のＢｏＮＴ／Ｅの生物学的活性を決定するための手段及び方法
TWI704156B (zh) * 2015-03-04 2020-09-11 德商曼茲法瑪股份有限公司 用於增進肉毒桿菌神經毒素進入細胞之特定攝取的方法

Also Published As

Publication number Publication date
EP3556770A1 (en) 2019-10-23
US20130040368A1 (en) 2013-02-14
US20120122128A1 (en) 2012-05-17
KR20100139022A (ko) 2010-12-31
SI2271670T1 (sl) 2015-01-30
CA2715033A1 (en) 2009-09-17
EP3031825B1 (en) 2019-07-24
US20220144925A1 (en) 2022-05-12
RU2010140478A (ru) 2012-04-20
US20210171614A1 (en) 2021-06-10
PT2271670E (pt) 2014-11-28
CY1115771T1 (el) 2017-01-25
PL3031825T3 (pl) 2020-02-28
MY165032A (en) 2018-02-28
IL208097A (en) 2015-10-29
UA102247C2 (ru) 2013-06-25
CN102937653B (zh) 2015-09-09
US20200369749A1 (en) 2020-11-26
CN102937653A (zh) 2013-02-20
IL222737A0 (en) 2012-12-31
US20120225436A1 (en) 2012-09-06
JP6227597B2 (ja) 2017-11-08
BRPI0908578A2 (pt) 2014-10-29
PL2271670T3 (pl) 2015-05-29
EP3031825A1 (en) 2016-06-15
US20200392212A1 (en) 2020-12-17
EP2271670B1 (en) 2014-09-03
IL222737A (en) 2015-10-29
HK1225746A1 (en) 2017-09-15
IL208097A0 (en) 2010-12-30
US20230279083A1 (en) 2023-09-07
CN102356091A (zh) 2012-02-15
EP2271670A1 (en) 2011-01-12
EP4588519A2 (en) 2025-07-23
US20230235031A1 (en) 2023-07-27
MX2010010137A (es) 2010-10-25
JP2015214567A (ja) 2015-12-03
JP6522075B2 (ja) 2019-05-29
US9249216B2 (en) 2016-02-02
AU2009223161B2 (en) 2014-10-30
EP3851451A1 (en) 2021-07-21
RU2491293C2 (ru) 2013-08-27
HUE046037T2 (hu) 2020-01-28
JP5766954B2 (ja) 2015-08-19
ES2524312T3 (es) 2014-12-05
US20170283487A1 (en) 2017-10-05
SI3031825T1 (sl) 2019-12-31
ES2755505T3 (es) 2020-04-22
JP2013100304A (ja) 2013-05-23
CA2715033C (en) 2014-11-25
DK3031825T3 (da) 2019-10-28
BR122012027456A2 (pt) 2015-07-14
US10703806B2 (en) 2020-07-07
US11261240B2 (en) 2022-03-01
PT3031825T (pt) 2019-10-31
RU2012146463A (ru) 2014-05-10
LT3031825T (lt) 2020-02-10
DK2271670T3 (en) 2014-12-01
JP2018049020A (ja) 2018-03-29
EP2578601A1 (en) 2013-04-10
US8198034B2 (en) 2012-06-12
US11332518B2 (en) 2022-05-17
WO2009114748A1 (en) 2009-09-17
AU2009223161A1 (en) 2009-09-17
JP2015143689A (ja) 2015-08-06
NZ588029A (en) 2012-12-21
HRP20191886T1 (hr) 2019-12-27
SG2014009112A (en) 2014-04-28
JP2011526243A (ja) 2011-10-06
US20210340229A1 (en) 2021-11-04
CO6311001A2 (es) 2011-08-22
HK1151298A1 (en) 2012-01-27
KR101609894B1 (ko) 2016-04-08
JP6050401B2 (ja) 2016-12-21
EP4588519A3 (en) 2025-10-15
MY155049A (en) 2015-08-28

Similar Documents

Publication Publication Date Title
CY1122328T1 (el) Ανοσο-βασιζομενες δοκιμασιες δραστικοτητας οροτυπου a βοτουλινικης τοξινης
CY1119942T1 (el) Μεθοδοι θεραπειας της ψωριασης χρησιμοποιωντας ανταγωνιστες της il-17
TR201910084T4 (tr) Radyoaktif-etiketli prostat spesifik membran antijen inhibitörleri.
CY1121208T1 (el) Σκευασματα αντισωματος ναταλιζουμαμπης
BR112013020500A2 (pt) anticorpo isolado, recombinante ou purificado
BRPI0921805A2 (pt) anticorpos que especificamente bloqueiam a atividade biológica de um antígeno de tumor
EA201290134A1 (ru) Система экспрессии
CY1115639T1 (el) Διειδικα αγωνιστικα αντισωματα υποδοχεα θανατου
EP2313434A4 (en) ANTIBODIES FOR NEUTRALIZING BOTULINE NEUROTOXINES
DK201100184U1 (da) Method for immunizing an avian species
EA201270212A1 (ru) Способ изготовления элемента, содержащего минеральное волокно, и элемент, изготовленный этим способом
MY177564A (en) Anti-nr10 antibody and use thereof
CR20120577A (es) Anticuerpos hacia gdf8 humano
PL3702368T3 (pl) Przeciwciała o zmodyfikowanym powinowactwie do FcRn, które wspomagają klierens antygenu
BR112014010900A2 (pt) métodos de preparar sistema de catalisador
CY1122711T1 (el) Μεθοδος για την ενεργοποιηση και τη συζευξη βιομοριων
EA201201016A1 (ru) Антидоты антикоагулянтов
CR20140443A (es) Anticuerpos contra la metaloproteinasa de la matriz 9
BR112012006824A2 (pt) adesivo com saída de luz, sistema de iluminação e método de instalação de um adesivo com saída de luz.
UY31688A1 (es) Plaguicidas
CY1119492T1 (el) Παραγωγα καρβαμικα/ουριας
TR201819828T4 (tr) Anti-fosfolipaz d4 antikoru.
BRPI1007686A2 (pt) sistema de iluminação
MY154715A (en) Anti-nr10 antibody and use thereof
EP2475383A4 (en) FOR THE PEPTIDE PRODUCED FROM HSP65 6 SPECIFIC HUMANIZED ANTIBODIES AND USES THEREOF